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Abstract: Abstract
Objectives
The current study was designed to explore the associations between L-arginine
metabolites and muscle mass and function in old age, which are largely unknown.
Design
The study used a randomised, double-blind, placebo-controlled design.
Setting
The study was carried out in a laboratory setting.
Participants
50 healthy older adults [median age 70 years (IQR 67-73); 27 males].
Intervention
Participants undertook an 18-week resistance exercise program, and a nutritional
intervention (fish oil vs. placebo).
Measurements
Serum homoarginine, ornithine, citrulline, asymmetric dimethylarginine (ADMA), NG-
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
monomethyl-L-arginine (L-NMMA), and symmetric dimethylarginine (SDMA), maximal
voluntary contraction (MVC) and isokinetic torque of the knee extensors at 30° s-1
(MIT), muscle cross sectional area (MCSA) and quality (MQ) were measured at
baseline and after the intervention.
Results
No significant exercise-induced changes were observed in metabolite concentrations.
There were significant sex differences in the associations between metabolites and
muscle parameters. After adjusting for age, glomerular filtration rate and fish oil
intervention, citrulline (P=0.002) and ornithine (P=0.022) were negatively associated
with MCSA at baseline in males but not females. However, baseline citrulline was
negatively correlated with exercise-induced changes in MVC (P=0.043) and MQ
(P=0.026) amongst females. Furthermore, amongst males, baseline homoarginine was
positively associated with exercise-induced changes in MVC (P=0.026), ADMA was
negatively associated with changes in MIT (P=0.026), L-NMMA (p=0.048) and ornithine
(P<0.001) were both positively associated with changes in MCSA, and ornithine was
negatively associated with changes in MQ (P=0.039).
Conclusion
Therefore, barring citrulline, there are significant sex differences in the associations
between L-arginine metabolites and muscle mass and function in healthy older adults.
These metabolites might enhance sarcopenia risk stratification, and the success of
exercise programs, in old age.
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Abstract 
Objectives 
The current study was designed to explore the associations between L-arginine metabolites 
and muscle mass and function in old age, which are largely unknown.  
Design  
The study used a randomised, double-blind, placebo-controlled design.  
Setting  
The study was carried out in a laboratory setting. 
Participants 
50 healthy older adults [median age 70 years (IQR 67-73); 27 males].  
Intervention  
Participants undertook an 18-week resistance exercise program, and a nutritional intervention 
(fish oil vs. placebo). 
Measurements  
Serum homoarginine, ornithine, citrulline, asymmetric dimethylarginine (ADMA), NG-
monomethyl-L-arginine (L-NMMA), and symmetric dimethylarginine (SDMA), maximal 
voluntary contraction (MVC) and isokinetic torque of the knee extensors at 30° s-1 (MIT), 
muscle cross sectional area (MCSA) and quality (MQ) were measured at baseline and after 
the intervention.  
Results 
No significant exercise-induced changes were observed in metabolite concentrations. There 
were significant sex differences in the associations between metabolites and muscle 
parameters. After adjusting for age, glomerular filtration rate and fish oil intervention, 
citrulline (P=0.002) and ornithine (P=0.022) were negatively associated with MCSA at 
baseline in males but not females. However, baseline citrulline was negatively correlated with 
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exercise-induced changes in MVC (P=0.043) and MQ (P=0.026) amongst females. 
Furthermore, amongst males, baseline homoarginine was positively associated with exercise-
induced changes in MVC (P=0.026), ADMA was negatively associated with changes in MIT 
(P=0.026), L-NMMA (p=0.048) and ornithine (P<0.001) were both positively associated with 
changes in MCSA, and ornithine was negatively associated with changes in MQ (P=0.039).  
Conclusion 
Therefore, barring citrulline, there are significant sex differences in the associations between 
L-arginine metabolites and muscle mass and function in healthy older adults. These 
metabolites might enhance sarcopenia risk stratification, and the success of exercise 
programs, in old age. 
 
Key words: L-arginine metabolites, muscle mass, muscle function, old age, exercise. 
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Introduction  
Advancing age is associated with a loss of muscle mass (sarcopenia) of 0.5-2% per year in 
humans [1]. The main problem associated with sarcopenia is the concomitant loss of muscle 
function, also known as dynapaenia. The latter increases the likelihood of falls and reduces 
quality of life in old age [2]. Sarcopenia had an estimated economic cost of $18.5 billion in 
the year 2000 in the USA [3]. Several factors have been suggested to contribute to the 
development of sarcopenia such as physical inactivity, alterations in protein metabolism, 
alterations to diet, chronic low grade inflammation and motor unit loss [4]. However, the 
precise aetiology remains to be established.  
Nitric oxide (NO), an endogenous regulator of vascular homeostasis, synthesized by NO 
synthases (NOS) using the amino acid L-arginine as a substrate, is also involved in 
maintaining skeletal muscle homeostasis. There is good evidence that NO mediates force 
production, muscle blood flow regulation, myocyte differentiation, respiration, and glucose 
homeostasis [5]. However, measuring NO concentrations in vivo is problematic, given its 
relatively short half-life [6]. Investigating more stable, direct or indirect, biomarkers of NO 
synthesis in modulating muscle homeostasis might allow one to identify patients at risk of 
developing sarcopenia and/or benefitting from specific interventions, e.g. physical exercise. 
Homoarginine and the methylated arginines, asymmetric dimethylarginine (ADMA) and NG-
monomethyl-L-arginine (L-NMMA), have been shown to modulate, either positively 
(homoarginine) or negatively (ADMA and L-NMMA), NO synthesis [7-9]. The potential role 
of these metabolites in skeletal muscle homeostasis is supported by recent studies reporting 
cross-sectional association trends between homoarginine, ADMA and muscle strength in 
older populations [10, 11]. However, we are currently lacking data on the association between 
L-arginine pathway metabolites and comprehensive measures of muscle function, as well as 
muscle mass. Furthermore, as resistance exercise improves muscle function in older adults 
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[12], it would be of interest to determine whether specific L-arginine metabolites prior to 
resistance exercise are associated with the changes in muscle mass and function following 
exercise.  
The main aim of this study was to investigate the cross-sectional associations between L-
arginine pathway metabolites, muscle mass and function, in a cohort of healthy older adults. 
A secondary aim was to determine associations between pre-exercise L-arginine metabolites 
and changes in muscle mass and function after resistance exercise training. A group of 
healthy older adults without a history of chronic disease was selected to minimize the 
confounding impact of medications and disease states on skeletal muscle homeostasis [13, 
14].  
Methods 
Study population    
Fifty community-dwelling adults >65 years old (27 males and 23 females) were recruited. 
Participants had no history of cardiovascular disease, cancer, arthritis, respiratory disease, 
metabolic disease, recent fractures and loss of mobility. No subject was on daily analgesia, 
nutritional supplements, or participating in any resistance exercise training. However, two 
participants were taking medications: one female participant was prescribed angiotensin 
converting enzyme inhibitors for mild hypertension, and one male participant was prescribed 
allopurinol for gout. The study was approved by the University of Aberdeen College of Life 
Sciences and Medicine Ethics Review Board (CERB/2011/6/644) and registered at 
clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT02843009). Written consent was obtained 
after explanation of the aims, risks and potential discomfort associated with the study, which 
conformed to the declaration of Helsinki. These participants were part of a study investigating 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
the effects of fish oil consumption on adaptations to resistance exercise and so were randomly 
assigned to either consume 3.0 g/day safflower oil or 3.0 g/day fish oil [15]. 
Resistance exercise training 
Resistance exercise training was performed twice weekly for 18 weeks. Each training session 
included four sets of nine repetitions for each exercise: leg press, leg extension, leg curl and 
calf press. The load for each exercise was set at 70% of the participant’s one repetition 
maximum (1RM). This was assessed for each exercise at baseline and every six weeks, and 
the load re-adjusted accordingly.  
Muscle mass and function 
The following measurements were performed the morning after an overnight fast, as 
previously described [16]. Measurements were made prior to and at least 48-h after the 
completion of the resistance exercise training intervention.  
Knee extensor isometric and isokinetic torque 
Maximal isometric torque of the knee extensor muscles of the right leg was determined 
during a maximal voluntary contraction (MVC) with the participant seated on a Biodex 
dynamometer with a knee angle of 73°. With the same seating position, maximal isokinetic 
torque (MIT) of the knee extensors was measured at 30° s-1. 
Magnetic resonance imaging (MRI) 
Of the 50 subjects completing the intervention 45 were able to participate in MRI data 
collection (3 were claustrophobic and 2 had metal implants). All scans were carried out on a 
Philips Achieva 3.0 Tesla whole body MRI scanner using a 16-channel SENSE XL Torso 
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coil. Muscle Anatomical Cross Sectional Area (MCSA) was quantified mid-thigh. Muscle 
quality (MQ) was calculated as torque (knee extensor isometric strength) per unit MCSA. 
Anthropometric parameters 
Body weight, height and body mass index (BMI) were measured in each study participant at 
baseline. 
Biochemical parameters 
Before and after the intervention fasted blood samples were collected from a vein in the 
antecubital fossa into K+EDTA vacutainers, placed on ice and processed within 30 min. 
Samples were centrifuged for 10 min at 4 °C at 800g and plasma aliquoted and stored at -80 
°C until analysis.  
L-arginine metabolites, creatinine, creatine, and glomerular filtration rate 
An Aquity UPLC (Waters, Sydney, Australia) coupled to a qToF Premier high-resolution 
mass spectrometer (Waters, Sydney, Australia) was used to measure plasma concentrations 
of L-arginine, ADMA, citrulline, homoarginine, L-NMMA, ornithine, SDMA, creatinine and 
creatine (for details see Supplementary file). The estimated glomerular filtration rate (eGFR) 
was calculated according to the Modification of Diet in Renal Disease formula [17]. 
Statistical analysis 
Results are expressed as means ± SD, medians and interquartile ranges, or frequencies as 
appropriate. Variables were tested for normal distribution by using the Kolmogorov-Smirnov 
test. Between-group differences were assessed either by one-way ANOVA (normally 
distributed variables) or Mann-Whitney U test (non-normally distributed variables). 
Differences between baseline and post-exercise muscle mass and function were assessed 
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either by paired Student’s t-test (normally distributed variables) or Wilcoxon test (non-
normally distributed variables). In each sex, the effects of exercise and nutritional intervention 
on L-arginine metabolites, creatinine and creatine, were assessed by ANCOVA. Partial 
correlations, stratified by sex and adjusted for age and eGFR, assessed the relationship 
between L-arginine metabolites and parameters of skeletal muscle mass and function (MVC: 
primary outcome; MIT, MCSA and MQ: secondary outcomes). Analyses were adjusted for 
age, eGFR and fish oil supplementation as these factors influence both L-arginine metabolite 
concentrations and muscle strength and volume [15, 18-20]. Analyses were performed using 
IBM SPSS Statistics Version 23, Release 23.0.0.2 (SPSS Inc., Armonk, NY, USA). A two-
sided P<0.05 indicated statistical significance.  
Results 
 
Baseline characteristics  
There were no significant sex-related differences in age, BMI, eGFR and MQ (Table 1). 
MVC, MIT, MCSA and serum creatinine concentrations were significantly higher in males, 
whereas serum creatine concentrations were significantly higher in females. Serum L-
arginine, ADMA, L-NMMA, SDMA, ornithine and citrulline concentrations were similar in 
both sexes. However, serum homoarginine concentrations were significantly higher in males. 
Effects of exercise training on muscle parameters and arginine metabolites 
The 18-week resistance exercise training induced a significant increase in MVC (31  24 %, 
P<0.001), MIT (12  18 %, P<0.001), MCSA (3  5 %, P<0.001) and MQ (27  26 %, 
P<0.001) in the whole group, with similar effects in both sexes. Barring a significant 
reduction in serum L-arginine concentrations in males, there were no significant baseline vs. 
post-exercise differences in L-arginine metabolites, creatinine and creatine in both sexes 
(Table 2).  
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Females 
Baseline 
There were no significant correlations between L-arginine metabolites and parameters of 
muscle structure and function at baseline (Table 3). 
Exercise-induced changes  
There were significant negative correlations between baseline citrulline concentrations and 
exercise-induced changes in MVC and MQ, and a negative trend between citrulline and 
exercise-induced changes in MIT (Table 4). By contrast, no significant correlations were 
observed between homoarginine, ADMA, L-NMMA, SDMA, and ornithine and exercise-
induced changes in muscle structure and function.  
Males 
Baseline  
There were significant negative correlations between baseline ornithine and citrulline 
concentrations and MCSA. By contrast, there were no significant correlations between 
homoarginine, ADMA, L-NMMA, and SDMA and muscle parameters (Table 5). 
Exercise-induced changes  
Significant positive correlations were observed between homoarginine concentrations and 
MVC changes, and L-NMMA and ornithine concentrations and MCSA changes (Table 6). A 
positive trend was also observed between homoarginine and MQ changes. By contrast, 
significant negative correlations were observed between ADMA concentrations and MIT 
changes, and between ornithine concentrations and MQ changes.  
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Discussion 
 
We observed significant sex differences in the associations between specific L-arginine 
pathway metabolites and established parameters of muscle structure and function in a cohort 
of healthy older adults undertaking an exercise program. Negative correlations, either at 
baseline or after exercise-induced changes, were observed in both sexes between citrulline 
and muscle parameters. However, further correlations with ornithine, homoarginine, ADMA 
and L-NMMA, direct or indirect modulators of NO synthesis, were observed in males, but not 
females. The observed correlations were adjusted for age, eGFR and nutritional intervention.  
The negative correlations between serum citrulline concentrations and parameters of muscle 
structure and function in both older females and males is intriguing. Citrulline is a by-product 
of both the enzymatic synthesis of NO by NOS and of the catabolism of L-NMMA and 
ADMA by dimethylarginine dimethylaminohydrolase (DDAH) [21]. Ornithine, a product of 
the bioconversion of arginine by the enzyme arginase [22], also showed a significant negative 
correlation with baseline MCSA, but a significant positive association with exercise-induced 
MCSA changes, in males. There is good evidence that an increase in arginase activity, 
therefore an increased synthesis of ornithine and, potentially, citrulline, is associated with 
endothelial dysfunction and alterations in vascular homeostasis, possibly through reduced 
supply of L-arginine needed by NOS to produce NO or through direct vasculotoxic effects of 
ornithine [23]. This, in turn, might lead to reduced skeletal muscle blood flow and other 
alterations previously described as a result of reduced NO synthesis, particularly in males [5]. 
Elevations in ornithine concentrations might not only represent a marker of reduced MCSA at 
baseline, but could also identify subjects exhibiting a greater MCSA response after exercise. 
However, in view of the negative correlations observed between ornithine and exercise-
induced changes in MQ, further studies are needed to establish the role of ornithine and 
citrulline in sarcopenia risk stratification and response to exercise in old age.     
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Serum concentrations of homoarginine, a non-essential and non-proteinogenic amino acid 
synthesized from L-arginine by the enzyme arginine:glycine aminidino transferase (AGAT), 
were positively correlated with exercise-induced changes in MVC in males. It has been 
proposed that homoarginine is a substrate for NOS. The possible beneficial effects of higher 
homoarginine might be secondary to an increased NO synthesis either in myocytes or in the 
local arterial circulation. The latter has been shown to positively affect force production, 
muscle blood flow regulation, myocyte differentiation, respiration, and glucose homeostasis 
[5]. Moreover, endothelial dysfunction, a consequence of impaired NO synthesis, has been 
shown to reduce the anabolic effects of insulin on amino acid delivery, thus favoring the onset 
of sarcopenia [24]. Another potential beneficial effect of homoarginine on skeletal muscle 
involves its biosynthesis by AGAT, significantly expressed in myocytes [25], which also 
results in the formation of guanidinoacetate. The latter is further converted into creatine, by 
guanidinoacetate methyltransferase [26], which is known to be beneficial for muscle mass and 
function in older adults [27].  
We observed significant sex differences in serum homoarginine concentrations, with higher 
concentrations in males, in accordance with previous reports [28]. Putative mechanisms 
explaining the higher concentrations of homoarginine in males include a) the positive effects 
of methyltestosterone on guanidinoacetate, and possibly homoarginine, synthesis [29]; and b) 
the estrogen-mediated up-regulation of the cationic amino acid transporter 1, which facilitates 
the transport of homoarginine and other analogues into the cytoplasm, thus reducing 
circulating concentrations [30]. However, the latter hypothesis is not supported by the lack of 
significant sex-related differences in other arginine analogues interacting with this transporter, 
e.g. ADMA, SDMA and L-NMMA, in our study. In a previous study in older female nursing 
home patients, Pilz et al observed an association trend between serum homoarginine 
concentrations and higher knee extensor strength (P=0.065) after adjusting for age, BMI, 
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albumin, creatinine clearance and parathyroid hormone concentrations [10]. Our study 
provides additional evidence of a potential beneficial homoarginine-mediated effect on 
muscle homeostasis, particularly in males. 
The potential role of NO in modulating muscle structure and function in old age, particularly 
in males, is further supported by the negative correlation observed between ADMA, an 
endogenous NOS inhibitor, and exercise-induces changes in MIT in this group. ADMA-
mediated inhibition of NO synthesis might lead to endothelial dysfunction, reduced muscle 
blood flow and alterations in muscle metabolism, as previously described [5, 24]. However, 
the observation of a positive association between L-NMMA, another endogenous NOS 
inhibitor, and MCSA, challenges this theory. Nevertheless, Obayashi et al have recently 
reported significant negative associations between serum ADMA concentrations, reduced grip 
strength (P=0.001) and quadriceps strength (P=0.012 in a larger cohort of community-
dwelling older Japanese male and female adults [11].  
The observation of sex-specific correlations between L-arginine pathway metabolites and 
skeletal muscle mass and function is potentially relevant for several reasons. First, it suggests 
that the relationship between L-arginine metabolic pathways and muscle homeostasis is 
different between older males and females. Second, it might lead to the identification of novel 
biomarkers of either impaired muscle homeostasis and/or risk of sarcopenia in old age. Third, 
it might predict the outcome of exercise programs in specific patient groups. Fourth, it might 
help in the design of nutritional interventions targeting NO synthesis. 
Strengths of our study included the rigorous assessment of a comprehensive panel of L-
arginine metabolites and established parameters of muscle mass and function, the limited 
confounding effect of age-associated co-morbid states and prescribed medications, and the 
closely supervised exercise training program in all participants. Furthermore, the longitudinal 
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nature of the study design allowed predicting changes in the outcomes of interest, thereby 
increasing the evidence for causality. Limitations include the relatively small sample size and 
the generalizability of our findings to other older patient populations, particularly frail 
patients with significant sarcopenia and co-morbidity burden.  
In conclusion, our study suggests that specific L-arginine metabolites, directly or indirectly 
influencing NO synthesis, might play an important role in the modulation of skeletal muscle 
mass and function in old age, particularly in males. Pending further confirmation in different 
populations, the identified biomarkers of NO synthesis and muscle homeostasis might 
enhance sarcopenia risk stratification, and the success of exercise programs, in this patient 
group.  
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Table 1. Baseline characteristics  
Parameter Whole group 
(n=50) 
Males 
(n=27) 
Females 
(n=23) 
P-value* 
Age (years) 70 [67, 73] 69 [67, 72] 71 [68, 73] 0.544 
Height (cm) 169 [159, 176] 175 [172, 179] 159 [155, 168] <0.0001 
Weight (Kg) 72.115.1 78.115.0 65.112.3 0.002 
Body Mass Index (Kg/m2) 25.44.4 25.64.2 25.34.7 0.821 
Estimated GFR (mL/min) 8012 7712 8313 0.079 
Creatine (mol/L) 16876 13451 20883 0.001 
Creatinine (mol/L) 7912 8510 719 <0.0001 
Maximal voluntary contraction (Nm) 90 [75, 120] 115 [94, 138] 76 [68, 85] <0.0001 
Maximal isokinetic torque (Nm) 11637 14132 8614 <0.0001 
Muscle ACSA (cm2) 51 [38, 64] 63 [58, 68] 37 [32, 43] <0.0001 
Muscle quality (Nm/cm2) 2.00.5 1.90.5 2.10.5 0.293 
Arginine (mol/L) 30544 30250 30936 0.580 
Homoarginine (mol/L) 2.360.76 2.740.67 1.900.60 <0.0001 
Asymmetric dimetylarginine (mol/L) 0.520.10 0.520.11 0.520.10 0.999 
NG-monomethyl-L-arginine (mol/L) 0.05 [0.04, 0.06] 0.05 [0.03, 0.05] 0.05 [0.04, 0.07] 0.108 
Symmetric dimethylarginine (mol/L) 0.480.12 0.480.08 0.480.15 0.950 
Ornithine (mol/L) 84 [80, 94] 87 [81, 101] 83 [72, 89] 0.060 
Citrulline (mol/L) 40 [35, 49] 39 [33, 48] 41 [37, 49] 0.360 
 
Data shown as mean ± SD or median [IQR] as appropriate  
Legend: GFR, glomerular filtration rate; ACSA, anatomical cross sectional area; *, males vs. 
females. 
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Table 2. Baseline vs. post-exercise mean (95% CI) differences in arginine metabolites, 
creatinine, and creatine in males and females 
 
 Mean (95% CI) difference P-value 
Females   
Arginine -8 (-29 to 12) 0.393 # 
Homoarginine  +0.13 (-0.06 to 0.32) 0.184 
Asymmetric dimethylarginine -0.01 (-0.06 to 0.05) 0.839 
NG-monomethyl-L-arginine -0.01 (-0.02 to 0.00) 0.153 
Symmetric dimethylarginine -0.05 (-0.11 to 0.01) 0.097 
Ornithine -0.48 (-6.45 to 5.49) 0.869 # 
Citrulline -0.42 (-3.67 to 2.83) 0.790 
Creatinine -2 (-5 to 2) 0.322 
Creatine +2 (-23 to 26) 0.883 
   
Males   
Arginine -27 (-47 to -7) 0.010 
Homoarginine  -0.06 (-0.41 to 0.30) 0.745 
Asymmetric dimethylarginine +0.01 (-0.05 to 0.06) 0.883 
NG-monomethyl-L-arginine 0.00 (-0.01 to 0.01) 0.566 # 
Symmetric dimethylarginine -0.02 (-0.05 to 0.01) 0.204 
Ornithine -6.5 (-13.8 to -.74) 0.076 
Citrulline -0.84 (-2.84 to 1.17) 0.398 
Creatinine -2 (-5 to 1) 0.265 
Creatine -6 (-20 to 9) 0.428 
 
#, time * nutritional intervention interaction (P<0.05). 
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Table 3. Partial correlations* between baseline arginine metabolites and parameters of 
muscle mass and function in females  
 
 MVC  
(Nm) 
MIT  
(Nm) 
MCSA  
(cm2) 
MQ 
(Nm.cm2) 
Arginine r= -0.38 
P=0.129 
r= -0.39 
P=0.118 
r= +0.02 
P=0.946 
r= -0.34 
P=0.181 
HMA  r= -0.26 
P=0.314 
r= +0.06 
P=0.814 
r= -0.36 
P=0.160 
r= +0.05 
P=0.834 
ADMA r= +0.04 
P=0.880 
r= +0.40 
P=0.110 
r= +0.42 
P=0.092 
r= -0.31 
P=0.222 
L-NMMA r= -0.03 
P=0.907 
r= +0.28 
P=0.281 
r= +0.34 
P=0.179 
r= -0.24 
P=0.357 
SDMA r= +0.06 
P=0.813 
r= +0.18 
P=0.478 
r= +0.08 
P=0.750 
r= -0.02 
P=0.949 
Ornithine r= -0.28 
P=0.281 
r= -0.23 
P=0.371 
r= -0.25 
P=0.329 
r= -0.03 
P=0.907 
Citrulline r= +0.25 
P=0.329 
r= +0.19 
P=0.475 
r= -0.15 
P=0.573 
r= +0.31 
P=0.233 
 
*, adjusted for age and estimated glomerular filtration rate 
Legend: MVC, maximal voluntary contraction; MIT, maximal isokinetic torque; MCSA, 
muscle volume; MQ, muscle quality; HMA, homoarginine; ADMA, asymmetric 
dimethylarginine; L-NMMA, NG-monomethyl-L-arginine; SDMA, symmetric 
dimethylarginine.  
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Table 4. Partial correlations* between baseline arginine metabolites and post-exercise 
changes in parameters of muscle mass and function in females  
 
 %MVC  
(Nm) 
%MIT  
(Nm) 
%MCSA  
(cm2) 
%MQ 
(Nm.cm2) 
Arginine r= +0.03 
P=0.922 
r= -0.24 
P=0.364 
r= -0.37 
P=0.157 
r= -0.26 
P=0.337 
HMA  r= +0.18 
P=0.501 
r= -0.01 
P=0.988 
r= +0.07 
P=0.789 
r= -0.05 
P=0.852 
ADMA r= +0.10 
P=0.713 
r= -0.42 
P=0.108 
r= +0.04 
P=0.892 
r= +0.18 
P=0.505 
L-NMMA r= +0.14 
P=0.604 
r= -0.34 
P=0.191 
r= +0.08 
P=0.780 
r= -0.29 
P=0.283 
SDMA r= -0.10 
P=0.713 
r= -0.18 
P=0.504 
r= +0.24 
P=0.374 
r= -0.21 
P=0.444 
Ornithine r= +0.33 
P=0.213 
r= +0.03 
P=0.914 
r= -0.33 
P=0.212 
r= +0.25 
P=0.358 
Citrulline r= -0.51 
P=0.043 
r= -0.48 
P=0.060 
r= +0.04 
P=0.890 
r= -0.55 
P=0.026 
 
*, adjusted for age, estimated glomerular filtration rate, and intervention group 
Legend: MVC, maximal voluntary contraction; MIT, maximal isokinetic torque; MCSA, 
muscle volume; MQ, muscle quality; HMA, homoarginine; ADMA, asymmetric 
dimethylarginine; L-NMMA, NG-monomethyl-L-arginine; SDMA, symmetric 
dimethylarginine.  
Significant correlations (P<0.05) are highlighted in bold. 
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Table 5. Partial correlations* between baseline arginine metabolites and parameters of 
muscle mass and function in males  
 
 MVC  
(Nm) 
MIT  
(Nm) 
MCSA  
(cm2) 
MQ 
(Nm.cm2) 
Arginine r= -0.14 
P=0.538 
r= +0.02 
P=0.912 
r= -0.45 
P=0.035 
r= +0.07 
P=0.743 
HMA  r= +0.11 
P=0.619 
r= +0.27 
P=0.221 
r= +0.24 
P=0.289 
r= -0.04 
P=0.851 
ADMA r= -0.06 
P=0.802 
r= +0.22 
P=0.320 
r= -0.01 
P=0.989 
r= -0.08 
P=0.730 
L-NMMA r= -0.33 
P=0.139 
r= -0.28 
P=0.201 
r= -0.36 
P=0.100 
r= -0.14 
P=0.522 
SDMA r= -0.13 
P=0.552 
r= -0.12 
P=0.590 
r= -0.16 
P=0.477 
r= -0.04 
P=0.871 
Ornithine r= -0.05 
P=0.808 
r= -0.05 
P=0.817 
r= -0.48 
P=0.022 
r= +0.22 
P=0.321 
Citrulline r= -0.32 
P=0.144 
r= -0.33 
P=0.132 
r= -0.63 
P=0.002 
r= -0.01 
P=0.990 
 
*, adjusted for age and estimated glomerular filtration rate 
Legend: MVC, maximal voluntary contraction; MIT, maximal isokinetic torque; MCSA, 
muscle volume; MQ, muscle quality; HMA, homoarginine; ADMA, asymmetric 
dimethylarginine; L-NMMA, NG-monomethyl-L-arginine; SDMA, symmetric 
dimethylarginine.  
Significant correlations (P<0.05) are highlighted in bold. 
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Table 6. Partial correlations* between baseline arginine metabolites and post-exercise 
changes in parameters of muscle mass and function in males  
 
 %MVC  
(Nm) 
%MIT  
(Nm) 
%MCSA  
(cm2) 
%MQ 
(Nm.cm2) 
Arginine r= -0.12 
P=0.598 
r= -0.42 
P=0.059 
r= +0.21 
P=0.356 
r= -0.17 
P=0.463 
HMA  r= +0.48 
P=0.026 
r= +0.30 
P=0.189 
r= +0.23 
P=0.309 
r= +0.40 
P=0.068 
ADMA r= -0.29 
P=0.198 
r= -0.49 
P=0.023 
r= +0.37 
P=0.101 
r= -0.37 
P=0.096 
L-NMMA r= +0.14 
P=0.557 
r= -0.06 
P=0.793 
r= +0.44 
P=0.048 
r= +0.03 
P=0.909 
SDMA r= +0.17 
P=0.449 
r= +0.06 
P=0.781 
r= +0.04 
P=0.846 
r= +0.16 
P=0.476 
Ornithine r= -0.30 
P=0.191 
r= -0.25 
P=0.271 
r= +0.723 
P<0.001 
r= -0.45 
P=0.039 
Citrulline r= -0.24 
P=0.293 
r= -0.32 
P=0.163 
r= +0.25 
P=0.265 
r= -0.29 
P=0.209 
 
*, adjusted for age, estimated glomerular filtration rate, and intervention group 
Legend: MVC, maximal voluntary contraction; MIT, maximal isokinetic torque; MCSA, 
muscle volume; MQ, muscle quality; HMA, homoarginine; ADMA, asymmetric 
dimethylarginine; L-NMMA, NG-monomethyl-L-arginine; SDMA, symmetric 
dimethylarginine.  
Significant correlations (P<0.05) are highlighted in bold. 
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